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40 
ABSTRACT 41 
ADMIRE was a multi-center, randomized-controlled, open, phase IIB superiority trial in 42 
previously untreated Chronic Lymphocytic Leukemia (CLL). Conventional frontline therapy 43 
in fit patients is fludarabine, cyclophosphamide and rituximab (FCR). Initial evidence from 44 
non-randomized Phase II trials suggested that the addition of mitoxantrone to FCR (FCM-R) 45 
improved remission rates. 215 patients were recruited to assess the primary endpoint of 46 
complete remission (CR) rates according to IWCLL criteria. Secondary endpoints were 47 
progression-free survival (PFS), overall survival (OS), overall response rate, minimal residual 48 
disease (MRD) negativity and safety. At final analysis, CR rates were 69.8% FCR vs. 69.3% 49 
FCM-R [adjusted odds ratio (OR):0.97; 95%CI:(0.53-1.79), p=0.932]. MRD-negativity rates 50 
were 59.3% FCR vs. 50.5% FCM-R [adjusted OR:0.70; 95%CI:(0.39-1.26), p=0.231]. During 51 
treatment, 60.0% (n=129) of participants received G-CSF as secondary prophylaxis for 52 
neutropenia, a lower proportion on FCR compared with FCM-R (56.1% vs 63.9%). The 53 
toxicity of both regimens was acceptable. There are no significant differences between the 54 
treatment groups for PFS and OS. The trial demonstrated that the addition of mitoxantrone to 55 
FCR did not increase the depth of response. Oral FCR was well tolerated and resulted in 56 
impressive responses in terms of CR rates and MRD negativity compared to historical series 57 
with intravenous chemotherapy. 58 
 59 
 60 
 61 
 62 
 63 
 64 
INTRODUCTION 65 
Chronic lymphocytic leukaemia (CLL) is a lymphoproliferative disorder accounting for 30% 66 
of adult leukaemia and 25% of Non-Hodgkin Lymphoma. CLL is the commonest form of 67 
leukaemia above the age of 50 years with a median age of diagnosis of 70 years. The treatment 68 
of CLL is tailored around the physical state of the patient due to toxicity associated with the 69 
chemotherapy-based treatments. 70 
CLL is still an incurable disease, and most patients will eventually become resistant to 71 
treatment. For physically fit patients, combination chemo-immunotherapy in the form of 72 
fludarabine, cyclophosphamide and rituximab (FCR) has become the standard of care based on 73 
evidence from large randomised controlled trials(1-3). Updated analysis suggested an 74 
improvement in progression free survival (PFS) and overall survival (OS) in patients treated 75 
with FCR over FC(1, 4). Hence, this combination is considered to be the gold-standard first-76 
line treatment in patients deemed to be suitable for fludarabine-based treatment. 77 
The addition of mitoxantrone to fludarabine-based therapy has been found to induce high 78 
response rates in a variety of lymphoproliferative disorders including follicular NHL(5) and 79 
mantle cell lymphoma(6). The addition of mitoxantrone to fludarabine and cyclophosphamide 80 
(FCM) has been assessed in a phase II clinical trial in which 69 CLL patients requiring therapy 81 
were given this combination as frontline treatment(7). This trial reported a CR rate of 64% with 82 
Minimal Residual Disease (MRD) negativity rate of 26% and Overall Response Rate (ORR) 83 
of 90%. The same group reported the combination of FCM-R in 72 previously untreated 84 
patients resulting in an ORR of 93% and a CR rate of 82% of which 46% achieved an MRD-85 
negative CR(8) which appeared higher than expected for FCR. FCM-R has also been reported 86 
in patients with relapsed/refractory CLL. Two trials involving 60 and 29 patients with relapsed 87 
refractory CLL reported an ORR with FCM of 78% and 79%, respectively, with 30 (50%) and 88 
9 (32%) patients, achieving a CR(9, 10). We previously reported a randomised phase II trial of 89 
52 patients with relapsed CLL, with ORR with FCM and FCM-R of 58% and 65%, 90 
respectively(11) and an acceptable toxicity profile. Eight (15.4%) patients in this trial achieved 91 
MRD negativity. 92 
The ADMIRE (Does the ADdition of Mitoxantrone Improve REsponse to FCR chemotherapy 93 
in patients with CLL) trial was designed to assess whether the addition of mitoxantone to FCR 94 
increases the depth of response in previously untreated patients with CLL requiring therapy in 95 
comparison to the standard FCR treatment. The current literature suggests that patients who 96 
respond to therapy and do not have detectable CLL by extremely sensitive techniques have a 97 
significantly prolonged survival(12-14). Therefore, one of the key secondary objectives was to 98 
compare MRD negativity within each treatment group. 99 
 100 
PATIENTS AND METHODS 101 
Trial Design 102 
ADMIRE was a multi-center, randomized, controlled, open-label, parallel-group, phase IIB 103 
superiority trial assessing FCR (control) versus FCM-R (experimental) for previously untreated 104 
patients with CLL requiring treatment by IWCLL criteria(15). Patients were randomly 105 
allocated via a central computer-generated minimization programme that incorporated a 106 
random element 1:1 to receive oral fludarabine, cyclophosphamide and intravenous rituximab 107 
with or without intravenous mitoxantrone. Randomization was stratified to ensure balance for 108 
center, Binet Stage (Progressive A or B, C), age group !DQGsex. 109 
The primary objective of the trial was to assess whether the addition of mitoxantrone to FCR 110 
improved CR rates in patients with previously untreated CLL. The results would be used to 111 
determine whether a larger randomized Phase III trial to formally assess survival was 112 
appropriate.  113 
An independent Data Monitoring Committee (DMC) was established to review the safety and 114 
ethics of the trial. The DMC reviewed unblinded safety data on a six-monthly basis and 115 
unblinded safety and trial progress reports on an annual basis. The DMC reported to an 116 
established trial steering committee (TSC) that provided general oversight for the trial. 117 
The trial was approved by relevant institutional ethical committees and regulatory review 118 
bodies, and was conducted in accordance with the Declaration of Helsinki and Good Clinical 119 
Practice. The trial was registered as an International Standard Randomized Controlled Trial 120 
(ISRCTN42165735); and on the European Clinical Trials Database (EudraCT: 2008-006342-121 
25). 122 
Patients 123 
The trial was planned to include 218 patients from hospitals around the United Kingdom (UK). 124 
Eligible patients had: progressive CLL requiring treatment by IWCLL criteria(15); no prior 125 
treatment for CLL; WHO performance status 0-2; Binet Stage progressive A, B or C; and 126 
provided written consent. Patients were not eligible if they had Hepatitis B or C; an active 127 
secondary malignancy (excluding basal cell carcinoma of the skin); an active infection; or past 128 
history of anaphylaxis following exposure to rat- or mouse-derived complementarity 129 
determining region (CDR)-grafted humanized monoclonal antibody. Patients with creatinine 130 
clearance greater than 30 ml/min were allowed to enter the trial with guidance on dose 131 
reduction for fludarabine. Patients with a 17p-deletion were eligible for enrollment due to lack 132 
of treatment options at the time of designing the trial.  Patients were able to withdraw from the 133 
trial at any time. 134 
Treatment and Assessments 135 
Treatment with FCR or FCM-R was repeated every 28 days for a total of six cycles. 136 
Fludarabine and cyclophosphamide were administered orally at doses of 24 mg/m2/day and 137 
150 mg/m2/day, respectively, for the first five days of each cycle. These doses are 138 
pharmacologically equivalent to the doses used when FCR is given intravenously for CLL(16). 139 
Mitoxantrone was administered intravenously on day 1 at a dose of 6 mg/m2 in the FCM-R 140 
group. Rituximab was administered intravenously at 375 mg/m2 on day 1 of cycle 1 and 500 141 
mg/m2 in cycles 2-6. In participants with lymphocyte counts greater than 25x109/L, the dose 142 
of rituximab was split to 100 mg on day 1 with the remaining dose given on day 2 to reduce 143 
the risk of infusion related reactions. Participants unable to tolerate oral chemotherapy were 144 
permitted to receive equivalent intravenous doses of fludarabine (25 mg/m2/day for 3 days) and 145 
cyclophosphamide (250mg/m2/day for 3 days). All participants were given allopurinol at least 146 
in cycle 1. PCP prophylaxis and acyclovir were given throughout the treatment. Secondary 147 
prophylaxis with granulocyte-colony stimulating factor (G-CSF) was recommended for 148 
patients experiencing scheduled delays due to neutropenia. Appropriate dose reductions were 149 
recommended in patients with therapy-related cytopenias. 150 
Participants were assessed for response at 3 months post treatment and at 12, 18 and 24 months 151 
post randomization in the absence of disease progression requiring treatment. Long-term 152 
annual follow-up for survival is being performed until death. 153 
Endpoints 154 
The primary endpoint was CR rate (including CRi) at 3 months post treatment. Response was 155 
centrally assessed according to IWCLL criteria(15) by two independent, experienced CLL 156 
haematologists blinded to treatment allocation. An independent arbiter reviewed discordant 157 
reports.  158 
Secondary endpoints at 3 months post treatment included: MRD negativity assessed in the bone 159 
marrow by highly sensitive multi-parameter flow cytometry with a level of detection below 1 160 
CLL cell in 10 000 leukocytes(14); ORR defined as at least partial remission (PR); and safety 161 
and toxicity as graded by CTCAE V3.0(17). 162 
Longer-term secondary endpoints included PFS, OS and time to MRD relapse in participants 163 
who became MRD negative.  164 
Sample Size 165 
The sample size was based on testing the null hypothesis of no difference in CR rates between 166 
the treatment groups. The CR rate with FCR was estimated to be 50%, with a clinically 167 
important improvement considered to be 20%. With a 2-sided 5% level of significance and 168 
80% power, 103 participants were required in each group. Allowing for a 5% dropout rate, the 169 
recruitment target was 218 participants. 170 
Statistical Methods 171 
All analyses were conducted on the intention-to-treat (ITT) population, in which participants 172 
were included according to their randomized treatment. Safety analyses included participants 173 
according to treatment received. 174 
Methods for handling missing endpoint data were pre-specified and approved by the Chief 175 
Investigator. Participants with a missing assessment who died from CLL or treatment-related 176 
toxicity prior to their primary endpoint assessment, or discontinued treatment early due to non-177 
response or toxicity, were treated as non-responders/MRD-positive. In the formal statistical 178 
analysis of the primary endpoint, for participants with at least a PR but missing trephine data 179 
to confirm a CR, imputation methods treated MRD-negative participants as having a CR and 180 
MRD-positive as not, although summaries report the un-imputed data. Participants without an 181 
available endpoint assessment were not included in the formal statistical analysis of the primary 182 
endpoint. This was appropriate as it can be assumed that data are missing completely at random 183 
(MCAR), since assessments were most likely unavailable due to samples being un-assessable 184 
or missed in error, rather than participant refusal due to level of response or treatment 185 
allocation. Sensitivity analyses assessed the robustness of the assumptions regarding missing 186 
primary endpoint data.  187 
Binary logistic regression models compared CR rates, proportions with undetectable MRD and 188 
ORR between the treatment groups, adjusted for the minimization factors, excluding center. The 189 
differences in proportions are reported with 95% confidence intervals (CIs).  190 
Kaplan-Meier curves are presented for the PFS and OS endpoints. Restricted mean survival 191 
time (RMST), used in the event of non-proportional hazards (18), estimated the area under the 192 
PFS curves, and treatment groups were compared using generalized linear regression, adjusted 193 
for the minimization factors, excluding center. Cox regression analysis formally compared OS 194 
between treatment groups. Participants without evidence of an event at the time of analysis 195 
were censored at the last date they were known to be alive and event-free.  196 
Safety analyses summarized the number of safety events occurring after randomization 197 
including treatment-related mortalities (within 3 months post-treatment) and incidence of 198 
secondary cancers.  199 
Pre-specified exploratory subgroup analyses assessed the heterogeneity of the treatment effect 200 
among subgroups of interest for the primary endpoint, PFS and OS. Formal statistical testing 201 
between subgroups was not appropriate due to multiple testing errors and the reduced numbers 202 
in each subgroup. Subgroup analyses were interpreted with caution and treated as hypothesis 203 
generating.  204 
 205 
RESULTS: 206 
Patient Characteristics 207 
Two-hundred and fifteen participants were recruited between July 2009 and April 2012 (FCR: 208 
107, FCM-R: 108) from 29 UK institutions with local ethical and management approval. The 209 
planned recruitment period ended before the target of 218 could be met. At the time of 210 
reporting, it has been approximately 7 years since the trial opened to recruitment, with a median 211 
follow-up of 5 years.  212 
The CONSORT diagram(19) (Figure 1) shows the flow of participants through the trial. The 213 
baseline characteristics are displayed in Table 1. The median age was 62 years (range 33±77) 214 
with 74 participants (34.4%) aged >65 years. There was a male predominance [163 (75.8%)] 215 
and 27 participants (12.6%) were Binet stage progressive A, 111 (51.6%) stage B and 77 216 
(35.8%) stage C. A majority of participants [124 (57.7%)] were WHO performance status (PS) 217 
0, with 83 (38.6%) PS 1 and 8 (3.7%) PS 2. Overall, 98 participants (45.6%) had B-symptoms 218 
[FCR: 51 (47.7%); FCM-R: 47 (43.5%)], whilst 123 (57.2%) had a ȕ-microglobulin 219 
concentration of PJ/ and 30 (14.0%) had creatinine clearance levels of 30-60 mls/min. Of 220 
the evaluable participants, 14/203 (6.9%) had a 17p deletion (FCR: 9/100 (9.0%); FCM-R: 221 
5/103 (4.9%)) and 38/203 (18.7%) an 11q deletion (FCR: 18/100 (18.0%); FCM-R: 20/103 222 
(19.4%)). 127/201 participants (63.2ZHUH FRQVLGHUHG WREH µSRRUer ULVN¶ LQ WHUPVRIVH 223 
mutational status i.e. VH unmutated or involving the VH3-21 gene [FCR: 68/101 (67.3%); 224 
FCM-R: 59/100 (59.0%)].     225 
Treatment 226 
Of the 215 participants, 154 (71.6%) received 6 cycles of treatment [FCR: 82 (76.6%); FCM-227 
R: 72 (66.7%)] (Table 2), and 24 (11.2%) received cycles of treatment [FCR: 11 (10.3%); 228 
FCM-R: 13 (12.0%)]. Four participants did not receive any protocol treatment [FCR: 3 (2.8%); 229 
FCM-R: 1 (0.9%)], three did not meet the eligibility criteria, and one participant allocated to 230 
receive FCR was removed by the treating clinician (Figure 1). Sixty-one participants (28.4%) 231 
discontinued treatment prematurely [FCR: 25 (23.4%); FCM-R: 36 (33.3%)] (Table 2). 232 
Reasons included: toxicity (n=43); progressive disease (n=2); stable disease with no/minimal 233 
response (n=2); ineligibility (n=4); participant choice (n=3); clinician decision (n=5); other 234 
(n=2). Overall, 129 (60.0%) participants received G-CSF during treatment as recommended in 235 
the protocol as secondary prophylaxis, with a higher proportion in the FCM-R group [FCR: 60 236 
(56.1%); FCM-R: 69 (63.9%)]. Twenty participants unable to tolerate oral chemotherapy 237 
received equivalent intravenous doses [FCR: 8 (7.5%), FCM-R: 12 (11.1%)]. 238 
Efficacy 239 
Of the 215 participants, 125 (58.1%) achieved a CR [FCR: 60 (56.1%); FCM-R: 65 (60.2%)] 240 
(Table 3).   In the formal analysis of the primary endpoint including imputation based on MRD 241 
outcome, 137/197 (69.5%) achieved a CR, with a similar proportion in each treatment group 242 
[FCR: 67/96 (69.8%); FCM-R: 70/101 (69.3%)] (Table 3). The difference in response rates 243 
(FCM-R ± FCR) was -0.5% (95% CI: -13.3%, 12.4%). In the logistic regression analysis, the 244 
odds ratio (OR) for achieving a CR with FCM-R compared to FCR was 0.97 (95% CI: 0.53, 245 
1.79), p-value=0.932, concluding that the difference between the groups is not significant at 246 
the 5% level. The sensitivity analyses did not alter the findings. 247 
There were no large differences in proportion of participants achieving a CR by gender [Male: 248 
100/148 (67.6%), Female: 37/49 (75.5%)], age group > 91/130 (70.0%), >65: 46/67 249 
(68.7%)] or Binet stage [Progressive A/B: 93/130 (71.5%), C: 44/67 (65.7%)]. A significantly 250 
higher proportion of participants who received >3 cycles of treatment achieved a CR [>3cycles: 251 
135/183 (73.8%);  cycles: 2/14 (14.3%); difference (95%CI): -59.5% (-78.9%, -40.1%)]. 252 
Lower proportions of participants with a 17p-deletion, 11q-deletion and µpoorer risk¶ VH 253 
mutational status achieved a CR [17pdel: 5/11 (45.5%); no 17pdel: 124/176 (70.5%)], [11qdel: 254 
23/37 (62.2%); no 11qdel: 106/150 (70.7%)], [VH unmutated or VH3-21: 76/117 (65.0%); VH 255 
mutated: 52/69 (75.4%)]. 256 
Of the 215 participants, 191 (88.8%) achieved at least a PR [FCR: 93 (86.9%), FCM-R: 98 257 
(90.7%)] Of the assessable participants, the ORR was 97.0% (191/197), with a similar 258 
proportion in each treatment group [FCR: 93/96 (96.9%), FCM-R: 98/101 (97.0%), with a 259 
difference (FCM-R ± FCR) of 0.15% (95% CI: -4.6%, 5.0%). A binary logistic regression 260 
analysis was unable to be performed due to the small number of participants in the non-261 
responders group. 262 
Of the 215 participants, 101 (47.0%) achieved MRD negativity assessed in the bone marrow 263 
three-months post-therapy [FCR: 54 (50.5%); FCM-R: 47 (43.5%) (Table 3).  In the formal 264 
analysis of MRD (excluding participants with a missing MRD assessment), 101/184 (54.9%) 265 
achieved MRD negativity [FCR: 54/91 (59.3%), FCM-R: 47/93 (50.5%)]. There was a non-266 
significant trend towards FCM-R resulting in lower MRD negativity rates at 3 months post-267 
treatment with a difference (FCM-R ± FCR) of -8.8% (95% CI: -23.1%, 5.5%), adjusted OR: 268 
0.70 [95% CI: (0.39, 1.26), p=0.231] (Table 3). 269 
At the time of analysis (4-years post-randomization of the final participant), 42 (19.5%) 270 
participants have died [FCR: 24 (22.4%), FCM-R: 18 (16.7%)], and 89 (41.4%) have either 271 
progressed or died [FCR: 44 (41.1%), FCM-R: 45 (41.7%)]. Figure 2 presents the PFS and OS 272 
Kaplan-Meier curves by treatment group.  The mean PFS time up to a restricted time of 72 273 
months post randomization was 51.7 and 52.3 months in the FCR and FCM-R groups, 274 
respectively. The difference in the restricted mean survival between the treatment groups was 275 
not significant [FCM-R vs FCR: parameter estimate: 0.48, SE: 3.23, p=0.8823]. For OS, the 276 
hazard ratio (HR) (FCM-R vs FCR) was not significant in the adjusted Cox regression model 277 
[HR&95%CI: 0.75 (0.41, 1.39), p=0.3596].  278 
Of the 101 participants who were MRD negative in the bone marrow at 3 months post treatment 279 
(Table 3), 23 (22.8%) have either relapsed at the MRD level in the peripheral blood or 280 
progressed [FCR: 11/54 (20.4%), FCM-R: 12/47 (25.5%)]. The curves are not presented due 281 
to the small number of events.  282 
For the planned subgroup analyses, Kaplan-Meier curves demonstrated an improved PFS for 283 
participants who achieved a CR or MRD negativity at 3 months post-treatment, and for those 284 
with a VH mutated gene (and not VH3-21) LHµVWDQGDUGULVN¶SDWLHQWV (Figure 3). Subgroup 285 
analyses for OS show similar trends. 286 
Safety and Toxicity 287 
The safety population included 212 participants (Figure 1). 156 SAEs were reported from 97 288 
(45.8%) participants, a lower proportion receiving FCR (41.9%) compared to FCM-R (49.5%).  289 
116 Serious Adverse Reactions (SARs) were reported from 76 (35.8%) participants [FCR: 55 290 
events from 36 (34.3%); FCM-R: 61 events from 40 (37.4%)]. The most commonly reported 291 
SARs, 65.5% of events (n=76) were infections and infestations. Ninety-two (43.4%) 292 
participants required hospitalization for an SAE [FCR: 43 (41.0%); FCM-R: 49 (45.8%)] 293 
(Table 4).  294 
One Suspected Unexpected Serious Adverse Reaction (SUSAR) was reported from a 295 
participant receiving all 6 cycles of FCM-R. They experienced prolonged myelosuppression 296 
and had a hypoplastic marrow on their 3-month post-treatment bone marrow aspirate. The 297 
event was suspected to be related to F, C and M. 298 
Non-serious adverse events (AEs) were reported from 210 (99.1%) participants, with similar 299 
proportions in each treatment group. Of the 2914 AEs reported, 468 (16.1%) were graded as 300 
CTCAE grade 3 or above [FCR: 222 (15.9%); FCM-R: 246 (16.2%)] (Table 4). 301 
There was one treatment-related mortality reported within 3 months of the end of protocol 302 
treatment from a participant receiving FCR.  303 
Within 5 years of participants ending treatment, 39 participants (18.4%) had been diagnosed 304 
with a secondary cancer [FCR: 19 (18.1%); FCM-R: 20 (18.7%)]. The most commonly 305 
reported secondary cancers were non-melanoma skin cancers in 6.1% (n=13) of participants, 306 
followed by non-hematological solid tumors in 5.7% of participants (n=12) (Table 4). 307 
 308 
DISCUSSION 309 
This multi-center collaborative trial demonstrates that oral FCR results in extremely high 310 
response and MRD negative rates (ORR: 97%, CR: 70%, MRD negativity: 59%). Trial follow-311 
up is still relatively immature (median 5 years) and there are a high number of censored 312 
observations but to date the PFS and OS are favorable compared to previous studies. The mean 313 
PFS for both trial arms is similar with no significant difference. PFS was improved in 314 
participants achieving CR and MRD negativity. Participants with mutated VH genes (excluding 315 
VH3-21) had improved PFS compared to those with unmutated VH genes or using VH3-21. The 316 
FCM-R group results appear equivalent, but the depth of responses was no higher with the 317 
addition of mitoxantrone to FCR (OR rate: 97%; CR rate: 69%; MRD negativity rate: 51%). 318 
The MRD negativity rate in bone marrow at 3 months post treatment is lower in the FCM-R 319 
group, although the difference is not statistically significant (p=0.231). The median age of 320 
participants was 62 years, which is comparable to other front-line CLL trials of fludarabine-321 
based therapies. 89% of the participants received greater than three cycles of treatment, and 322 
72% of the participants received all six cycles of treatment. PCP and acyclovir prophylaxis was 323 
recommended for all participants. Secondary prophylaxis with G-CSF was administered to 324 
60% of participants, enabling the delivery of a maximum number of treatment cycles. This may 325 
explain the high response and MRD-negative rates in our trial. The dose of fludarabine was 326 
reduced by 50% in participants with creatinine clearance between 30-60 mls/min. The 30 327 
(14%) participants with creatinine clearance of 30-60 mls/min had a similar CR/CRi rate of 328 
73.4%.  This might suggests that selected participants considered unfit for FCR due to renal 329 
dysfunction can tolerate dose-modified FCR with high response rates.  330 
A slightly higher proportion of participants experienced a SAR with FCM-R (FCR: 34.3% vs 331 
FCM-R: 37.4%) and the number of SARs reported overall was higher for FCM-R (FCR: 55 vs 332 
FCM-R: 61). A similar proportion of grade 3 or 4 AEs were experienced in each treatment 333 
group (FCR: 15.9% vs FCM-R: 16.2%).  334 
In summary, we have demonstrated that the addition of mitoxantrone to frontline FCR did not 335 
improve responses but slightly increased toxicity. In view of this, FCM-R will not be taken 336 
forward into a larger definitive Phase III trial. The trial demonstrated that oral FCR given at an 337 
equivalent dose to intravenous FCR yields extremely high response rates compared to historical 338 
series and was well tolerated. This is consistent with the outcome of its companion trial 339 
ARCTIC comparing FCR with FCM-miniR (reported in the companion paper). The 340 
explanation for the high response rates is not certain but is possibly due to the fact that in the 341 
oral regime the same dose of chemotherapy is spread over 5 rather than 3 days and that the 342 
duration of therapy exposure per cycle may be critical. In addition, dose intensity was 343 
optimised by mandating primary prophylaxis with acyclovir and co-trimoxazole, and 344 
secondary prophylaxis with G-CSF.  It was also possible to use dose adjusted FCR for 345 
participants with impaired renal function. 346 
FCR therefore remains the gold-standard therapy for CLL in participants considered fit for 347 
fludarabine-based therapy against which the novel targeted therapies must be tested, with oral 348 
administration of FC giving results at least as good as those obtained with IV administration. 349 
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Figure 1. CONSORT Diagram 470 
  471 
Assessed for eligibility (n=420) 
Excluded (n=205): 
- Patient clinically ineligible (n=112) 
- Patient does not wish to participate (n=39) 
- Patient too ill to participate (n=4) 
- Other reasons (n=50) 
Analysis populations: 
 
Intention-to-treat population (n=96) 
- Excluded from ITT (n=11) 
o Lost-to-follow-up (n=11) 
 
Safety population (n=105) 
- Excludes 3 FCR participants who failed to receive any 
treatment 
- Includes 1 FCM-R participant who received 1 cycle of FCR 
Patient withdrawn consent from trial (n=2): 
- From further trial treatment only (n=1) 
- From further clinical data collection only (n=1) 
- From further trial treatment and follow-up data collection 
(n=0) 
Patient withdrawn by clinician (n=1): 
- µSHUFHQWRIFHOOVKDYH73ORVV¶Q  
Ineligible post-randomisation (n=3): 
- Does not have B-CLL with characteristic immunophenotype 
(n=1) 
- Active or prior Hepatitis B or C (n=1) 
- Active secondary malignancy (excluding basal cell carcinoma) 
(n=1) 
Lost to follow-up: missing primary endpoint data (n=11): 
- Missing trephine sample (n=5) 
- Ineligible post-randomisation (n=3) 
- Withdrawn by clinician (n=1) 
- Unable to assess response due to insufficient clinical 
evaluations (n=2) 
 
Allocated to FCR (n=107) 
Received FCR (n=104) 
Did not receive FCR (n=3) 
- Breach of eligibility criteria (n=2) 
- Withdrawn by clinician (n=1) 
Patient withdrawn consent from trial (n=4): 
- From further trial treatment only (n=2) 
- From further clinical data collection only (n=0) 
- From further trial treatment and follow-up data collection 
(n=2) 
Patient withdrawn by clinician (n=1): 
- Reason unknown (n=1) 
 
Ineligible post-randomisation (n=1): 
- Prior therapy for CLL (n=1) 
 
 
Lost to follow-up: missing primary endpoint data (n=7): 
- Missing trephine sample (n=4) 
- Ineligible post-randomisation (n=1) 
- Unable to assess response due to insufficient clinical 
evaluations (n=1) 
- Withdrew from follow-up data collection prior to assessment 
of primary endpoint (n=1) 
 
Allocated to FCM-R (n=108) 
Received allocated intervention (n=107) 
Did not receive allocated intervention (n=1) 
- Breach of eligibility criteria (n=1) 
Analysis populations: 
 
Intention-to-treat population (n=101) 
- Excluded from ITT (n=7) 
o Lost to follow-up (n=7) 
 
Safety population (n=107) 
- Excludes 1 FCM-R participant who received 1 cycle of FCR 
 
Randomised (n=215) 
Table 1. Baseline Characteristics  472 
 
FCR 
(n=107) 
FCM-R 
(n=108) 
Total 
(n=215) 
Age (at randomization)    
 70 (65.4%) 71 (65.7%) 141 (65.6%) 
>65 37 (34.6%) 37 (34.3%) 74 (34.4%) 
Mean (s.d.) 61.5 (8.0) 61.7 (8.1) 61.6 (8.0) 
Median (range) 61 (38, 76) 63 (33, 77) 62 (33, 77) 
Sex    
Male 82 (76.6%) 81 (75.0%) 163 (75.8%) 
Female 25 (23.4%) 27 (25.0%) 52 (24.2%) 
Binet Stage     
Progressive A 13 (12.1%) 14 (13.0%) 27 (12.6%) 
B 59 (55.1%) 52 (48.1%) 111 (51.6%) 
C 35 (32.7%) 42 (38.9%) 77 (35.8%) 
B-symptoms    
Yes 51 (47.7%) 47 (43.5%) 98 (45.6%) 
No 56 (52.3%) 60 (55.6%) 116 (54.0%) 
Missing 0 (0.0%) 1 (0.9%) 1 (0.5%) 
WHO performance status    
0 59 (55.1%) 65 (60.2%) 124 (57.7%) 
1 43 (40.2%) 40 (37.0%) 83 (38.6%) 
2 5 (4.7%) 3 (2.8%) 8 (3.7%) 
Beta-2 microglobulin concentration 
(mg/L)    
<4 mg/L 39 (36.4%) 45 (41.7%) 84 (39.1%) 
PJ/ 64 (59.8%) 59 (54.6%) 123 (57.2%) 
Missing 4 (3.7%) 4 (3.7%) 8 (3.7%) 
Creatinine clearance (mls/min)    
30-60mls/min 17 (15.9%) 13 (12.0%) 30 (14.0%) 
>60mls/min 85 (79.4%) 93 (86.1%) 178 (82.8%) 
Missing 5 (4.7%) 2 (1.9%) 7 (3.3%) 
 FCR 
(n=107) 
FCM-R 
(n=108) 
Total 
(n=215) 
17p deletion    
Yes (poorer risk) 9 (8.4%) 5 (4.6%) 14 (6.5%) 
No (standard risk) 91 (85.0%) 98 (90.7%) 189 (87.9%) 
Missing 7 (6.5%) 5 (4.6%) 12 (5.6%) 
11q deletion    
Yes (poorer risk) 18 (16.8%) 20 (18.5%) 38 (17.7%) 
No (standard risk) 82 (76.6%) 83 (76.9%) 165 (76.7%) 
Missing 7 (6.5%) 5 (4.6%) 12 (5.6%) 
VH mutational risk status    
VH unmutated or VH3-21(poorer risk) 68 (63.6%) 59 (54.6%) 127 (59.1%) 
 VH mutated and not VH3-21 (standard risk) 33 (30.8%) 41 (38.0%) 74 (34.4%) 
Unknown 6 (5.6%) 8 (7.4%) 14 (6.5%) 
 473 
WHO: World Health Organisation 474 
 475 
 476 
 477 
 478 
 479 
 480 
 481 
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 484 
 485 
 486 
 487 
 488 
Table 2.   Treatment Summaries 489 
 
FCR 
(n=107) 
FCM-R 
(n=108) 
Total 
(n=215) 
Discontinued treatment prematurely (received 
<6 cycles)?    
Yes 25 (23.4%) 36 (33.3%) 61 (28.4%) 
No 82 (76.6%) 72 (66.7%) 154 (71.6%) 
Treatment cycles received    
 cycles 11 (10.3%) 13 (12.0%) 24 (11.2%) 
> 3 cycles 96 (89.7%) 95 (88.0%) 191 (88.8%) 
Received G-CSF during treatment (cycles 2 - 
6)?    
Yes 60 (56.1%) 69 (63.9%) 129 (60.0%) 
No 43 (40.2%) 34 (31.5%) 77 (35.8%) 
Unknown 4 (3.7%) 5 (4.6%) 9 (4.2%) 
 490 
G-CSF: Granulocyte-colony stimulating factor was given if there was significant neutropenia 491 
on a previous cycle of treatment 492 
 493 
 494 
 495 
 496 
 497 
 498 
 499 
 500 
 501 
 502 
 503 
 504 
 505 
Table 3. Efficacy Summaries 506 
MRD NEGATIVITY 
MRD status 
FCR 
(n=107) 
FCM-R 
(n=108) 
Total 
(n=215) 
MRD negative 54 (50.5%) 47 (43.5%) 101 (47.0%) 
MRD positive 37 (34.6%) 46 (42.6%) 83 (38.6%) 
Missing 16 (15.0%) 15 (13.9%) 31 (14.4%) 
MRD status FCR (n=91) 
FCM-R 
(n=93) 
Difference in MRD-
negative rates 
& 95% CIs 
(FCM-R - FCR) 
MRD negative 54 (59.3%) 47 (50.5%) -8.8% (-23.1%, 5.5%) 
MRD positive 37 (40.7%) 46 (49.5%)  
Logistic regression analysis for the % of participants achieving MRD negativity 
Parameter* Parameter 
estimate SE OR & 95% CIs 
FCM-R vs FCR -0.36 0.30 0.70 (0.39, 1.26) 
COMPLETE RESPONSE 
CR status (prior to 
imputation using 
MRD) 
FCR 
(n=107) 
FCM-R 
(n=108) 
Total 
(n=215) 
Achieved a CR 60 (56.1%) 65 (60.2%) 125 (58.1%) 
Did not achieve a CR 22 (20.6%) 27 (25.0%) 49 (22.8%) 
Missing 25 (23.4%) 16 (14.8%) 41 (19.1%) 
CR status (post 
imputation using 
MRD) 
FCR 
(n=107) 
FCM-R 
(n=108) 
Total 
(n=215) 
Achieved a CR 67 (62.6%) 70 (64.8%) 137 (63.7%) 
Did not achieve a CR 29 (27.1%) 31 (28.7%) 60 (27.9%) 
Missing 11 (10.3%) 7 (6.5%) 18 (8.4%) 
CR status (post 
imputation using 
MRD) 
FCR 
(n=96) 
FCM-R 
(n=101) 
Difference in CR rates 
& 95% CIs 
(FCM-R - FCR) 
Achieved a CR 67 (69.8%) 70 (69.3%) -0.5% (-13.3%, 12.4%) 
Did not achieve a CR 29 (30.2%) 31 (30.7%)  
PRIMARY ENDPOINT ANALYSIS 
Logistic regression analysis for the % of participants achieving a CR 
Parameter* Parameter 
estimate SE OR & 95% CIs 
FCM-R vs FCR -0.03 0.31 0.97 (0.53, 1.79) 
 507 
CR: Complete remission (CR/CRi) 508 
MRD: Minimal Residual Disease 509 
SE: Standard error  510 
OR: Odds ratio 511 
*Adjusted estimate of the treatment effect from the multivariable logistic regression model, 512 
adjusted for the minimization factors 513 
 514 
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 527 
 528 
 529 
 530 
 531 
 532 
Table 4 Safety and Toxicity Summaries 533 
 
FCR 
(n=105) 
FCM-R 
(n=107) 
Total 
(n=212) 
Serious Adverse Events (SAEs) 
Number of participants 
experiencing an SAE 44 (41.9%) 53 (49.5%) 97 (45.8%) 
Total number of SAEs 
reported 72 84 156 
Number of participants 
requiring hospitalization 
for an SAE 
43 (41.0%) 49 (45.8%) 92 (43.4%) 
Serious Adverse Reactions (SARs) 
Number of participants 
experiencing a SAR 36 (34.3%) 40 (37.4%) 76 (35.8%) 
Total number of SARs 
reported 55 61 116 
SARs by MedDRA 
System Organ Class*    
Blood and lymphatic 
system disorders 4 (7.3%) 7 (11.5%) 11 (9.5%) 
Cardiac disorders 1 (1.8%) 1 (1.6%) 2 (1.7%) 
Gastrointestinal disorders 4 (7.3%) 2 (3.3%) 6 (5.2%) 
General disorders and 
administration site 
conditions 
9 (16.4%) 8 (13.1%) 17 (14.7%) 
Hepatobiliary disorders 0 (0.0%) 1 (1.6%) 1 (0.9%) 
Infections and infestations 36 (65.5%) 40 (65.6%) 76 (65.5%) 
Injury, poisoning and 
procedural complications 0 (0.0%) 1 (1.6%) 1 (0.9%) 
Renal and urinary 
disorders 1 (1.8%) 0 (0.0%) 1 (0.9%) 
Respiratory, thoracic and 
mediastinal disorders 0 (0.0%) 1 (1.6%) 1 (0.9%) 
Adverse Events (AEs) 
Number of participants 
experiencing an AE 103 (98.1%) 107 (100%) 210 (99.1%) 
 FCR 
(n=105) 
FCM-R 
(n=107) 
Total 
(n=212) 
CTCAE grade    
<3 1171 (83.9%) 1269 (83.6%) 2440 (83.7%) 
 222 (15.9%) 246 (16.2%) 468 (16.1%) 
Missing 3 (0.2%) 3 (0.2%) 6 (0.2%) 
Total 1396 (100%) 1518 (100%) 2914 (100%) 
Secondary Cancers 
Number of participants 
reporting each secondary 
cancer 
   
Hematological 
(Lymphoma) 4 (3.8%) 2 (1.9%) 6 (2.8%) 
Hematological 
(AML/MDS) 3 (2.9%) 3 (2.8%) 6 (2.8%) 
Skin (Non-melanoma) 4 (3.8%) 9 (8.4%) 13 (6.1%) 
Skin (Melanoma) 1 (1.0%) 2 (1.9%) 3 (1.4%) 
Non-hematological (Solid 
tumors) 6 (5.7%) 6 (5.6%) 12 (5.7%) 
Unknown 1 (1.0%) 1 (0.9%) 2 (0.9%) 
 534 
*Percentages out of the total number of SARs reported 535 
MedDRA: Medical Dictionary for Regulatory Activities 536 
CTCAE: Common Terminology Criteria for Adverse Events 537 
AML: Acute myeloid leukemia 538 
MDS: Myelodysplastic syndrome 539 
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Figure 2. Kaplan-Meier Curves for Progression-Free and Overall Survival 545 
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